SOD3 improves the tumor response to chemotherapy by stabilizing endothelial HIF-2α

Emilia Mira1, Lorena Carmona-Rodríguez1, Beatriz Pérez-Villamil2, Josefina Casas3, María Jesús Fernández-Aceñero2, Diego Martínez-Rey1, Paula Martín-González1, Ignacio Heras-Murillo1, Mateo Paz-Cabezas2, Manuel Tardáguila1,6, Tim D. Oury4, Silvia Martín-Puig5, Rosa Ana Lacalle1, Gemma Fabriás3, Eduardo Díaz-Rubio2 & Santos Mañes1

One drawback of chemotherapy is poor drug delivery to tumor cells, due in part to hyper-permeability of the tumor vasculature. Extracellular superoxide dismutase (SOD3) is an antioxidant enzyme usually repressed in the tumor milieu. Here we show that specific SOD3 re-expression in tumor-associated endothelial cells (ECs) increases doxorubicin (Doxo) delivery into and chemotherapeutic effect on tumors. Enhanced SOD3 activity fostered perivascular nitric oxide accumulation and reduced vessel leakage by inducing vascular endothelial cadherin (VEC) transcription. SOD3 reduced HIF prolyl hydroxylase domain protein activity, which increased hypoxia-inducible factor-2α (HIF-2α) stability and enhanced its binding to a specific VEC promoter region. EC-specific HIF-2α ablation prevented both the SOD3-mediated increase in VEC transcription and the enhanced Doxo effect. SOD3, VEC, and HIF-2α levels correlated positively in primary colorectal cancers, which suggests a similar interconnection of these proteins in human malignancy.

1 Department of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, Darwin, 3, Madrid, 28049, Spain. 2 Genomics and Microarray Laboratory, Medical Oncology & Surgical Pathology Departments, Instituto de Investigación Sanitaria San Carlos Hospital Clínico San Carlos, Univ. Complutense de Madrid, CIBERONC, Profesor Martín Lagos, S/N, Madrid, 28040, Spain. 3 Department of Biomedical Chemistry, Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), Jordi Girona 18-26, Barcelona, 08034, Spain. 4 Department of Pathology, University of Pittsburgh, 3550 Terrace Street, Pittsburgh, PA 15261, USA. 5 Myocardial Pathophysiology Area, Centro Nacional de Investigaciones Cardiovasculares, Calle de Melchor Fernández Almagro, 3, Madrid, 28029, Spain. 6 Present address: Genetics Institute, University of Florida, 2033 Mowry Road, Gainesville, FL 32610, USA. E. Mira and L. Carmona-Rodríguez contributed equally to this work. Correspondence and requests for materials should be addressed to S. Mñes (email: smanes@cnb.csic.es).
The endothelium forms the inner blood vessel barrier that regulates fluid, molecule and cell exchange between blood and interstitial tissues. From a molecular viewpoint, this endothelial barrier relies on several cell-cell adhesion systems in endothelial cells (ECs), including adherens junctions (AJ), and tight junctions (TJ), whose control is essential for vascular homeostasis. In cancer, endothelial junction composition and function undergo extreme alterations that lead to massive edema and increased interstitial pressure; this reduces tumor perfusion and limits delivery of therapeutic agents. Impaired blood flow in leaky vessels also aggravates hypoxia, which leads tumor cells greater resistance to anticancer compounds. Preservation of the endothelial barrier is thus of great clinical interest in oncology.

Vascular endothelial cadherin (VEC; cadherin 5, CD144) is responsible for endothelial AJ assembly and barrier architecture. VEC mediates homophilic adhesion through cadherin repeats in its extracellular domain. The VEC intracellular region interacts with cytoplasmic proteins such as β-catenin and p120-catenin; these anchor VEC to the actin cytoskeleton and control VEC-elicited signals including modulation of the EC response to angiogenic factors, quiescence and polarity signals, and EC interaction with mural cells. VEC also regulates transcription of the TJ protein claudin-5, which pinpoints VEC as a cornerstone in EC intercellular junction organization. In embryos and adults, slight changes in VEC function, localization, or expression severely destabilizes the vasculature. Given its role in EC junction strength and plasticity, changes in VEC levels or trafficking are recurrently altered manifestations of the twisted, leaky blood vessel network in tumors.

Low oxygen tension, or hypoxia, is a hallmark of the tumor microenvironment and a major factor leading to EC dysfunction. The adaptive cellular response to hypoxia is mediated by the basic helix-loop-helix/PERN-ARNT-SIM hypoxia-inducible transcription factors (HIF-1 and -2), heterodimers composed of HIF-α and -β subunits. HIF-β subunits are constitutively expressed and stable, whereas HIF-α subunits are regulated precisely by the HIF prolyl hydroxylase domain proteins (PHD1–3). In normoxic conditions, PHD enzymes hydroxylate two proline residues of HIF-α, which triggers binding of the Von Hippel-Lindau (VHL) E3 ubiquitin ligase to this subunit, and its subsequent ubiquitination and degradation. In hypoxia, PHD become inactive, which stabilizes HIF-α subunits and triggers functional HIF heterodimers. Increased HIF levels in cancer cells induce overproduction of angiogenic factors such as vascular endothelial growth factor (VEGF), which in turn promotes angiogenesis and vessel leakiness. Systemic postnatal ablation of PHD2 induces hyperactive angiogenesis due to HIF-1 (but not HIF-2) stabilization in internal organs. EC-specific partial reduction of PHD2 levels does not increase vascular density in tumors, however; it tightens EC adhesion by increasing VEC transcription, which improves vascular function and chemotherapeutic drug delivery. These effects are associated with HIF-2α (but not HIF-1α) stabilization in PHD2−/− haploinsufficient EC; HIF-2α (also termed EPAS-1) but not HIF-1α induces VEC transcription.

Preclinical and clinical evidence shows that HIF-2α inhibitors reduce neangiogenesis and growth of human renal clear cell carcinomas, a neoplasia characterized by HIF-1α inactivation. HIF-2α effects on the tumor milieu thus appear to be cell type specific and dose dependent, suggesting that cancer therapy can be enhanced by selective, precise HIF-2α stabilization in endothelial but not in cancer cells.

Nitric oxide (NO) is a regulator of PHD activity and hence of HIF-α levels. In normoxia, NO stabilizes HIF-1α in epithelial cells by inhibiting PHD. Perivascular NO accumulation also reduces vascular permeability, increases tumor oxygenation, and improves response to radiotherapy. NO levels must nonetheless be regulated precisely, since both inhibition and excess NO synthesis can induce AJ disassembly and vascular hyperpermeability. These paradigmatic NO activities could be a result of its reaction with other environmental co-signals such as the superoxide free radical (O₂·−). O₂·− concentrations not only determine NO steady-state levels but also the formation of highly reactive nitrogen species such as peroxynitrite (ONOO−); indeed, HIF-α stability in human cerebral vascular smooth muscle cells (VSMCs) depends on NO and O₂·− levels.

SOD3 (or extracellular superoxide dismutase) is a secreted enzyme that regulates the tissue redox balance by catalyzing O₂·− dismutation to H₂O₂. In contrast to intracellular SOD, SOD3 is expressed strongly in specific tissues and cells, including ECs. SOD3 has a tissue-protective role in the perivascular space by preventing oxidative damage of proteins and lipids and by preserving NO availability. By controlling NO/O₂·− reactions, SOD3 enhances NO-dependent vasorelaxation, which highlights its importance in vascular function. SOD3 effects on cancer biology, particularly on tumor vasculature, are poorly understood, although low SOD3 levels are associated with increased cancer incidence and poor prognosis. Here we used pharmacological and genetic approaches to determine that restoration of SOD3 levels in tumors regulates tumor vasculature and increases the tumor response to chemotherapy.

Results

SOD3 upregulation potentiates doxorubicin effect on tumors. We first analyzed whether SOD3 affects the tumor response to chemotherapy, SOD3 is usually downregulated in tumors compared to normal tissue. Lovastatin (Lov) upregulates SOD3 in spontaneous mammary tumors in mice, which make Lov a useful strategy for inducing SOD3 in the tumor environment.

We generated subcutaneous tumors by injecting Lewis lung adenocarcinoma (LLC) cells in syngeneic wild-type (WT) and SOD3-deficient mice (SOD3−/−). SOD3−/− mice do not display any overt phenotype in basal conditions, and there were no major differences in EC marker expression compared to WT mice (Supplementary Fig. 1). Tumor-bearing mice were treated daily with a Lov dose equivalent to that in humans treated with 40 mg/day, or with vehicle (Vhcl) as control, starting at day 7 post-implant. A suboptimal doxorubicin (Doxo) dose was co-administered to mice. Although Lov alone did not affect tumor growth kinetics, it increased the Doxo antitumor effect in WT (Fig. 1a) but not in SOD3−/− mice (Fig. 1b). This enhancement correlated with a two-fold increase in Doxo levels in Lov compared to Vhcl-treated WT mouse tumors (Fig. 1c); Lov treatment had no effect on Doxo levels in tumors in SOD3−/− mice.

Lov induced SOD3 in LLC tumors in WT but not in SOD3−/− mice (Supplementary Fig. 2a, b); this induction was also apparent in tumor sections (Fig. 1d). Although SOD3 is a soluble protein that can diffuse in the extracellular milieu, we observed a tendency to perivascular SOD3 accumulation in Lov-treated tumors grown in WT hosts. Staining of 3-nitrotyrosine (3-NT; a surrogate oxidative stress marker) in LLC tumors was reduced by Lov treatment in WT but not in SOD3−/− mice (Fig. 1e); these data linked the SOD3 increase to higher antioxidant activity in tumors from Lov-treated WT mice. To define the Lov-targeted cell types, SOD3 mRNA was quantified in LLC cells, leukocytes (CD45+), and ECs (CD31+) isolated from tumors grown in Vhcl- and Lov-treated WT and SOD3−/− mice. Lov minimally changed SOD3 mRNA in LLC cells in both mouse types (Fig. 1f) but induced a significant increase in leukocytes and ECs isolated from tumors in WT mice (Fig. 1f). This SOD3 upregulation was not observed in leukocytes or ECs from tumor-free spleen and lung.
Fig. 1 SOD3 upregulation enhances Doxo chemotherapeutic effects. 

**a**, **b** LLC tumor growth kinetics in Vhcl-, Lov-, Doxo+Vhcl-, or Doxo+Lov-treated WT (a) and SOD3−/− mice (b). Arrows indicate treatment schedule (n=10 mice/group). 

**c** Tumors from WT or SOD3−/− mice treated as above were dissected on day 16 and Doxo was quantified in tumor extracts. 

**d** Vhcl- and Lov-treated tumors from WT or SOD3−/− mice were dissected on day 18 (<1 cm³), and SOD3 and CD31 were detected in cryosections by immunohistochemistry (IHC); the two-color merge is shown (n=10 fields/group; 4 mice/group). 

**e** 3-NT detection in paraffin sections of LLC tumors as in **d** (n=15 fields/group; 4 mice/group). 

**f** LLC-GFP cells were implanted in WT or SOD3−/− mice, Lov-treated as in **a**, and tumors were dissected on day 21. LLC cells, ECs, and leukocytes were isolated by cell sorting and SOD3 mRNA was determined by qPCR. Data shown as mean ± SEM of triplicates (n=5 mice/group). 

**g** Detection of SOD3 expression (red) and CD31 (green) in sections of Ad-C- or Ad-mSOD3-injected LLC tumors (dissected on day 18); nuclei are DAPI-stained (blue). Arrows in the SOD3 panel indicate the position of CD31+ cells. Bottom panel shows SOD3 fluorescence intensity quantified by ImageJ (15 images/group; 4 mice/group). 

**h** Growth kinetics of Ad-C- or Ad-mSOD3-injected LLC tumors. Arrows indicate treatment schedule (n=9 mice/group). 

**i** Doxo quantification in extracts of tumors dissected on day 16 from mice treated as in **h**. *p < 0.05, **p < 0.01, ***p < 0.001 one-way ANOVA with Dunnett’s post-hoc test using Vhcl group as reference (a, b) or two-tailed Student’s t-test (f–i). Bar, 10 μm (d, g) and 50 μm (e).
from the Lov-treated mice (Supplementary Fig. 3a) nor when Lov was added to the cultured 1G11 murine EC line or to 3T3 fibroblasts (Supplementary Fig. 3b, c). In our model, Lov induced SOD3 mainly in stromal cells in a tumor-specific manner.

Tumor necrosis factor (TNF-α) downregulates SOD3 in 3T3 cells, and Lov reduces TNF-α expression in tumor-infiltrating leukocytes. Lov-induced SOD3 upregulation might be consequence of attenuation of inflammation in the tumor environment. In support of this idea, Lov reversed TNF-α-induced SOD3 inhibition in vitro in a dose-dependent manner (Supplementary Fig. 3d). TNF-α-induced SOD3 repression was also reversed by simvastatin but not by atorvastatin at the highest dose (Supplementary Fig. 3e). This suggests heterogeneity in the mechanism by which statins increase SOD3 levels.

**Forced SOD3 re-expression potentiates doxorubicin effect.** Statins are pleiotropic drugs with many effects on the vasculature and/or tumor cell growth. To link SOD3 directly to Doxo effectiveness, we injected a recombinant adeno virus (Ad-mSOD3) to overexpress murine SOD3 in LLC tumors grafted into SOD3−/− mice; these experiments were done with no Lov co-treatment. Compared to the weak SOD3 staining in Ad-C (β-galactosidase-encoding)-injected tumors, Ad-mSOD3 injection notably increased SOD3 staining in tumor and stromal cells (Fig. 1g). Owing to the ability of Ad-mSOD3 to infect both tumor and stromal cells, SOD3 production was distributed homogeneously throughout the tumor parenchyma. In the absence of Doxo, Ad-mSOD3- and Ad-C-injected tumor growth was comparable (Supplementary Fig. 4a), which suggested that SOD3 overexpression had no inherent protumor or antitumor activity. Ad-mSOD3 injection nonetheless enhanced the Doxo inhibitory effect on tumor growth (Fig. 1h), which again correlated with higher Doxo levels in Ad-mSOD3- compared to Ad-C-injected tumors (Fig. 1i). Pharmacological or genetic SOD3 upregulation in the tumor environment thus increased levels of the small compound Doxo in tumors.

**Intratumor SOD3 levels regulate EC structure and function.** We tested whether SOD3 upregulation altered perfusion of the tumor parenchyma. Blood vessel labeling with fluorescein isothiocyanate (FITC)-conjugated lectin showed that Ad-mSOD3 treatment increased the percentage of lectin+CD31+ vessels compared to Ad-C (Fig. 2a, Supplementary 4b), which implicates SOD3 directly in promoting tumor perfusion. Despite increased perfusion in Ad-mSOD3-injected tumors, we noted an unanticipated reduction in blood vessel number (Fig. 2b). Mean vessel area was nonetheless increased (Fig. 2c), which implied greater tumor irrigation. Analysis of CD31 staining in thick sections from Ad-C- and Ad-mSOD3-injected tumors (Fig. 2d) showed that SOD3 overexpression increased vessel length and diameter (Fig. 2e, f), although vessel branching was unaffected (Fig. 2g).

We also observed an increase in the percentage of vessels double stained with lectin and CD31 in Lov- compared to Vhcl-treated WT mice (Fig. 2h). When Lov and Doxo treatments were combined, perfusion also increased in WT mice (Supplementary Fig. 4c). In SOD3−/− mice, Lov treatment did not significantly enhance tumor perfusion compared to Vhcl, although there was a clear trend toward a higher percentage of lectin+CD31+ vessels in these mice (Fig. 2h). Lov treatment might thus have additional, SOD3-independent effects on tumor perfusion, possibly linked to its pleiotropic activities on the endothelium. Analysis of lectin+ vessels in thick sections from Vhcl- and Lov-treated tumors (Fig. 2i) indicated that, as observed in Ad-mSOD3-injected tumors, Lov treatment of WT mice increased mean vessel area and tumor vessel length (Fig. 2j, k), although blood vessel diameter decreased compared to Vhcl-treated mice (Fig. 2l).

These differences were not observed in tumors from Lov- and Vhcl-treated SOD3−/− mice, which indicates SOD3 influence on these changes. Vessel branching was comparable in all mice.

Scanning electron microscopy (SEM) suggested that Lov treatment altered vessel ultrastructure in tumors grown in WT mice, as lumens were smoother than those in Vhcl-treated WT or Lov-treated SOD3−/− mice (Fig. 2m). Lov treatment reduced tumor vessel leakage (dextran extravasation) in WT compared to Vhcl-treated but not in SOD3−/− mice (Fig. 2n, o). Alteration in VEC expression is sufficient to disrupt EC intercellular junctions. Lov-treated tumors in WT mice had higher MEC mRNA and protein levels than tumors from Vhcl-treated WT or Lov-treated SOD3−/− mice (Fig. 2p-r). The extension of VEC junctions increased in tumor vessels from Lov- compared to Vhcl-treated WT mice (4.7 ± 0.5 μm vs. 3.1 ± 0.2 μm; p < 0.05, two-tailed Student’s t-test; n = 35). This was not observed in SOD3−/− mice (Vhcl, 3.8 ± 0.3 μm, n = 83; Lov, 3.1 ± 0.2 μm, n = 38).

VEC-stained area in CD31+ structures was larger in Ad-mSOD3- than in Ad-C-injected tumors (Supplementary Fig. 4d,e). Ad-mSOD3 also enlarged the extension of VEC junctions compared to Ad-C (Ad-mSOD3, 7.1 ± 1.6 μm, n = 50; Ad-C, 2.9 ± 0.5 μm, n = 81; p < 0.05, two-tailed Student’s t-test), which indicates that SOD3 directly regulates VEC expression in tumor-associated ECs.

**SOD3 upregulation in ECs enhances intratumor Doxo levels.** We analyzed whether specific endothelial SOD3 expression enhanced tumor response to chemotherapy. To generate a conditional mouse strain, we crossed a loxP-SOD3KI mouse line (Fig. 3a) with an EC-specific inducible Cre-driver line (VE-Cad-CreERT2)37. Isogenic littermates, Cre+ SOD3 overexpression in EC; SOD3EC-Tg) or Cre− (no ectopic SOD3 expression), were inoculated with LLC cells, and EC-SOD3 overexpression was induced by two tamoxifen injections; higher tamoxifen doses impaired tumor angiogenesis, independently of SOD3 induction. Tamoxifen induced strong SOD3 expression in ~50% of tumor vessel ECs in Cre+ but not in Cre− mice (Fig. 3b). The Doxo antitumor effect was greater in SOD3EC-Tg than in Cre− littermates (Fig. 3c), and intratumor Doxo levels were higher in SOD3EC−/− mice (Fig. 3d). The percentage of lectin-perfused blood vessels was higher in SOD3EC−/− tumors compared to controls (Fig. 3e, f), which suggested improved tumor perfusion after EC-SOD3 expression. Analysis of CD31 indicated that EC-SOD3 expression reduced the total number of CD31-stained vessels (Fig. 3g, h), although the vessel-covered area was larger in SOD3EC−/− tumors (Fig. 3i). SOD3EC−/− tumor vessels were larger and of greater diameter than those in control mice (Fig. 3j, k), whereas vessel branching was unaffected by SOD3 (Fig. 3l).

The VEC-stained area relative to that of CD31 (Fig. 3m, n) and the extension of VEC junctions also increased in SOD3EC−/− vessels compared to controls (SOD3EC−/−, 2.7 ± 0.4 μm, n = 83; Cre−, 1.5 ± 0.1 μm, n = 130, p < 0.05, two-tailed Student’s t-test). The reduced dextran-red leakage in SOD3EC−/− vessels (Fig. 3o) also suggests a tighter EC barrier. Specific EC-SOD3 expression is sufficient to improve the LLC tumor response to chemotherapy and to increase EC barrier firmness.

**SOD3 induces VEC expression via a NO-dependent pathway.** We studied the mechanism by which SOD3 stimulates VEC gene transcriptions. The microvascular 1G11 endothelial cell line was transduced with a bicistronic retrovirus expressing green fluorescent protein (GFP) and SOD3. Enhanced SOD3 expression was verified by immunoblot of lysates from stable mock and
SOD3 transfectants (Supplementary Fig. 5a), although most SOD3 was secreted to the medium (Supplementary Fig. 5b). Dihydroethidium oxidation, used to measure \( \cdot \mathrm{O}_2^- \) levels, was lower in 1G11-SOD3- than in 1G11-mock-transduced cells, both in basal culture and after incubation with tumor cell-conditioned medium, a stress condition that boosted \( \cdot \mathrm{O}_2^- \) production in mock-transfected cells (Supplementary Fig. 5c). 1G11-SOD3 cells thus overexpress enzymatically functional SOD3.

SOD3 overexpression in 1G11 cells upregulated VEC expression compared to mock cells, as detected by immunoblot and reverse transcriptase quantitative PCR (RT-qPCR) (Fig. 4a, b); SOD3-induced VEC expression was also evident by

a

b

c

d

e

f

SOD3–/–  WT

Lectin

Dextran

WT + Lov

SOD3–/–

Vessel leakage

n.s.

Lov Vhcl

* n.s.

WT SOD3 –/–

Vessel leakage

n.s.

Lov Vhcl

* n.s.

WT SOD3 –/–

Mean vessel area (\( \mu \text{m}^2 \))

100

200

0

50

100

Mean vessel width (\( \mu \text{m} \))

10

15

0

5

Branches/vessel

1

2

0

g

h

i

j

k

l

m

n

SOD3–/–

SOD3–/–

WT + Lov

SOD3–/– + Vhcl

WT + Vhcl

SOD3–/–

SOD3–/–

WT SOD3 –/–

Vessel leakage

n.s.

Lov Vhcl

* n.s.

WT SOD3 –/–

Mean vessel length (\( \mu \text{m} \))

100

150

200

0

50

100

Mean vessel width (\( \mu \text{m} \))

10

15

0

5

Branches/vessel

1

2

0

g

h

i

j

k

l

m

n

SOD3–/–

SOD3–/–

WT + Lov

SOD3–/– + Vhcl

WT + Vhcl

SOD3–/–

SOD3–/–

WT SOD3 –/–

Vessel leakage

n.s.

Lov Vhcl

* n.s.

WT SOD3 –/–

Mean vessel length (\( \mu \text{m} \))

100

150

200

0

50

100

Mean vessel width (\( \mu \text{m} \))

10

15

0

5

Branches/vessel

1

2

0

g

h

i

j

k

l

m

n

SOD3–/–

SOD3–/–

WT + Lov

SOD3–/– + Vhcl

WT + Vhcl

SOD3–/–

SOD3–/–

WT SOD3 –/–

Vessel leakage

n.s.

Lov Vhcl

* n.s.

WT SOD3 –/–

Mean vessel length (\( \mu \text{m} \))

100

150

200

0

50

100

Mean vessel width (\( \mu \text{m} \))

10

15

0

5

Branches/vessel

1

2

0

g

h

i

j

k

l

m

n

SOD3–/–

SOD3–/–

WT + Lov

SOD3–/– + Vhcl

WT + Vhcl

SOD3–/–

SOD3–/–

WT SOD3 –/–

Vessel leakage

n.s.

Lov Vhcl

* n.s.

WT SOD3 –/–

Mean vessel length (\( \mu \text{m} \))

100

150

200

0

50

100

Mean vessel width (\( \mu \text{m} \))

10

15

0

5

Branches/vessel

1

2

0

g

h

i

j

k

l

m

n

SOD3–/–

SOD3–/–

WT + Lov

SOD3–/– + Vhcl

WT + Vhcl

SOD3–/–

SOD3–/–

WT SOD3 –/–

Vessel leakage

n.s.

Lov Vhcl

* n.s.

WT SOD3 –/–

Mean vessel length (\( \mu \text{m} \))

100

150

200

0

50

100

Mean vessel width (\( \mu \text{m} \))

10

15

0

5

Branches/vessel

1

2

0


immunofluorescence (IF) (Fig. 4c). Quantification of continuous- and discontinuous A + indicated that SOD3 increased the percentage of continuous VEC junctions (Fig. 4d) and reduced the number of intercellular gaps (Fig. 4e); these data suggest that SOD3 promotes EC interconnectivity. Permeability to dextran-FITC particles was lower in 1G11-SOD3 monolayers (Fig. 4f), which supports a role for SOD3 in vascular integrity. Overexpression of the inactive SOD3S195C mutant did not reduce 1G11 permeability (Fig. 4f), although mutant and WT enzyme expression were comparable (Fig. 4g). These results indicate the need for SOD3 enzyme activity to regulate EC permeability. SOD3 silencing in 1G11 cells reduced VEC expression, as detected by IF (Supplementary Fig. 6a–d). This reduction in VEC levels was associated with increased dextran-FITC permeability of SOD3-silenced 1G11 cell monolayers compared to controls (Supplementary Fig. 6e).

To further test whether SOD3 increased barrier stability, we analyzed permeability to dextran-FITC particles in VEGF-treated 1G11-SOD3 and mock cells. In accordance with its leakiness-inducing activity, VEGF increased permeability in 1G11-mock monolayers; this did not occur in 1G11-SOD3 cells (Fig. 4h). VEC staining (Fig. 4i) indicated that VEGF-treated mock cells showed a reduction in the length of continuous VEC junctions (Fig. 4i) and an increase in intercellular gaps (Fig. 4k); VEGF minimally affected these parameters in 1G11-SOD3 cells. The SOD3-induced increase in VEC expression thus counteracted VEGF-induced vessel leakiness.

SOD3 scavenging activity increases NO availability; fluorescence-activated cell sorting (FACS) analysis of the NO probe DAF2 showed higher intracellular NO levels in 1G11-SOD3 than in -mock cells (Fig. 4l, m). Analysis of NO distribution using the NO-sensitive probe 4,5-diamino-rhodamine B (DAR-1) in LLC tumors indicated that SOD3 induction by Lov increased DAR-1-associated fluorescence (formed after the NO reaction) near vascular structures in tumors from WT but not from SOD3−/− mice (Fig. 4n). A total of 76% of FITC-lectin+ structures in WT tumors (n=46) showed more intense DAR-1 staining than in adjacent parenchyma, whereas strong DAR-1 staining was seen in only 50% of SOD3−/− tumor vessels (n=34; p=0.016, Pearson’s χ²). These differences in the DAR-1 staining pattern cannot be attributed to a differential host-dependent Lov effect on NO synthesis, as endothelial NO synthetase (eNOS) expression in tumor-associated vasculature was comparable in Lov-treated WT and SOD3−/− mice (Fig. 4o), also observed in WT and SOD3−/− mice in basal conditions (Supplementary Fig. 1). SOD3 levels might influence perivascular NO levels in vitro and in vivo.

To further analyze the role of NO in the SOD3-mediated increase in EC barrier function, we treated 1G11-mock and -SOD3 cells with the NOS inhibitor L-NMMA prior to permeability analysis. Whereas Vhcl-treated 1G11-SOD3 monolayers were less permeable than those of 1G11-mock cells, L-NMMA treatment increased 1G11-SOD3 permeability to levels similar to controls (Fig. 4p). Moreover, whereas SOD3 overexpression in 1G11 cells increased luciferase activity driven by a ~2.5 kb VEC promoter, L-NMMA treatment reduced SOD3-induced VEC promoter activity to control levels (Fig. 4q). To confirm NO as a direct regulator of VEC transcription, we incubated VEC-luciferase reporter-transfected 1G11 cells with the NO donor (Z)-1-[N-(2-aminoethyl)-N-(2-ammonioethy) amino] diazan-1-ium-1,2-diolate (DETA-NONOate). Low DETA-NONOate doses increased VEC promoter-driven luciferase activity compared to Vhcl-treated cells, whereas very high DETA-NONOate concentrations inhibited VEC-driven transcription (Fig. 4r). In accordance with this biphasic NO effect on VEC promoter activity, low and high DETA-NONOate concentrations had opposite effects on 1G11 permeability to dextran-FITC (Fig. 4s). A dose-dependent NO-mediated mechanism thus appears to underlie SOD3-induced VEC transcription and EC barrier stability in 1G11 cells.

SOD3 overexpression in human dermal microvasculature-derived EC (HDMEC) and in bovine aortic EC (BAEC) also increased VEC mRNA and protein levels and reduced permeability to dextran-FITC in a NO-dependent manner (Supplementary Fig. 7). SOD3 effects on VEC expression and the EC barrier are therefore not restricted to mouse-derived ECs or due to clonal artifacts.

**HIF-2α mediates SOD3 enhancement of VEC transcription.** To identify the transcription factor involved in SOD3 induction of VEC transcription, we analyzed a series of truncated VEC promoters in mock- and SOD3-transfected 1G11 cells. SOD3 potentiated transcription driven by ~2.5 and ~1 kb VEC promoters but not of those <0.5 kb (Fig. 5a), which indicated critical SOD3 regulatory elements at the ~500 bp–1000 region. This region has three hypoxia response elements (HRE) and one KLF-4-binding site (Fig. 5b). HRE are HIF-1 and HIF-2 consensus binding sites. Only HIF-2α overexpression induced VEC promoter-driven transcription of a reporter gene (Supplementary Fig. 8a, b). These results support the reported specific HIF-2α role in VEC transcription. Chromatin immunoprecipitation (ChIP) with anti-HIF-2α and -KLF-4 antibodies showed SOD3-induced association of HIF-2α (but not KLF-4) to the VEC promoter ~500 bp–1000 region (Fig. 5c, ChIP2); HIF-2α or KLF-4 interaction at more distal promoter sites was nonetheless SOD3 independent (Fig. 5c, ChIP1).

Using directed mutagenesis, we determined the role of each HRE in the region critical for SOD3-induced VEC transcription. Elimination of the HRE1 site did not alter SOD3-mediated
enhancement of VEC promoter-driven activity, whereas mutation of HRE2 or HRE3 sites was sufficient to abolish the SOD3 transcription effect (Fig. 5d). These results identify SOD3 as a positive regulator of HIF-2α-mediated VEC transcription, probably by fostering HIF-2α association to HRE2 and HRE3 sites on the VEC promoter.

To further link HIF-2α to SOD3-induced VEC transcription, we used short hairpin RNA (shRNA) to stably silence this factor in 1G11 cells (Fig. 5e). HIF-2α knockdown reduced VEC mRNA levels in 1G11 cells (Fig. 5f); VEC levels in HIF-α-silenced cells were unchanged (Supplementary Fig. 8c, d), which supports a specific HIF-2α role in VEC transcription. SOD3 also activated the VEC promoter (1 kb) in shNT-1G11 (control) but not in shHIF-2α-silenced cells (Fig. 5g), which indicates that SOD3-induced VEC promoter activity is HIF-2α dependent. SOD3 increased luciferase activity driven by a synthetic promoter bearing 9× HRE sites (Supplementary Fig. 9a), which pinpoints SOD3 as a general activator of HIF-2α-mediated transcription.

**SOD3 stabilizes HIF-2α by curbing PHD activity.** We examined how SOD3 regulates HIF-2α activity. SOD3 overexpression did not appreciably change HIF-2α mRNA (Supplementary Fig. 9b) but increased HIF-2α protein levels (Fig. 6a). SOD3 not only augmented total HIF-2α staining but also increased the area and intensity of HIF-2α-stained nuclei in 1G11 (Fig. 6b–d) and in HDMEC (Supplementary Fig. 9c–e). Gradual HIF-2α overexpression triggered proportional VEC transcription (Supplementary Fig. 9f). SOD3-induced HIF-2α stabilization might thus explain SOD3-induced VEC transcription.
As NO negatively regulates PHD activity\(^1\), we tested whether SOD3 regulates HIF-2\(\alpha\) posttranslationally. Levels of PHD-2 (the most abundant isoform) were comparable in 1G11-SOD3 and -mock cells (Supplementary Fig. 9g), which suggested that SOD3 does not affect PHD abundance. The selective PHD-2 inhibitor IOX2\(^4\) increased VEC promoter-driven luciferase activity in 1G11-mock vs. Vhcl-treated cells but did not induce higher VEC promoter activity in 1G11-SOD3 cells than that observed after SOD3 overexpression (Fig. 6e); this implies that IOX2 and SOD3 act on the same pathway to boost VEC promoter-driven transcription.

To quantify PHD activity in mock- and SOD3-transfected cells, we established an enzyme-linked immunosorbent assay (ELISA) to detect proline hydroxylation of a peptide from the HIF-1\(\alpha\) oxygen-dependent degradation domain, with recombinant HA-tagged VHL (Fig. 6f). VHL discriminated between hydroxylated
and non-hydroxylated HIF-1α peptides (Supplementary Fig. 9h), which confirmed ELISA specificity. SOD3 overexpression reduced peptide hydroxylation (Fig. 6g), which was associated with reduced HIF-2α ubiquitination in 1G11-SOD3 cultured in normoxia (Fig. 6h). HIF-2α degradation was delayed after re-oxygenation of hypoxic cultured 1G11-SOD3 compared to mock cells (Fig. 6i, j); oxygen-induced HIF-1α degradation was unaffected by SOD3 overexpression (Supplementary Fig. 9i, j).

Our data showed more rapid HIF-1α decay after re-oxygenation than HIF-2α, which agrees with differential HIF-1α and HIF-2α sensitivity to oxygen-induced breakdown in ECs.12 The degree of SOD3-induced PHD inhibition might be insufficient to prevent this rapid HIF-1α degradation.

The nuclear HIF-2α-stained area and intensity were reduced in L-NMMA- than in Vhcl-treated 1G11-SOD3 cells (Fig. 6k–m), which implicates NO in SOD3-mediated HIF-2α stabilization. DETA-NONOate treatment increased VEC promoter-driven luciferase activity in HIF-2α- but not in mock-transfected 3T3 fibroblasts (Supplementary Fig. 9k). As 3T3 cells in normoxia do not express HIF-2α, our data indicate that NO induces VEC promoter-driven transcription by regulating HIF-2α levels.

HIF-2α ablation in EC impedes SOD3 effects on Doxo activity. To confirm the role of endothelial HIF-2α in mediating SOD3 effects on tumor vasculature, we analyzed the result of SOD3 overexpression on Doxo effectiveness in mice lacking HIF-2α in ECs (HIF-2αEC-KO), obtained by crossing HIF-2αfl/fl with VE-Cad-CreERT2 mice. HIF-2α- and VEC mRNA levels were reduced in EC isolated from tumors grafted in HIF-2αEC-KO mice vs. Cre−littermates after tamoxifen injection (Supplementary Fig. 10a, b), which supports HIF-2α as a VEC regulator in tumor endothelium.

To determine whether the improved, SOD3-induced response to chemotherapy is HIF-2α-dependent, we injected Ad-C or Ad-mSOD3 virus and Doxo into tumor-bearing tamoxifen-treated HIF-2αEC-KO or Cre− mice. Coinciding with our earlier data (Fig. 1h), Ad-mSOD3 increased Doxo activity in controls compared to Ad-C treatment (Fig. 7a), while the Ad-mSOD3 effect was lost when LLC tumors were grafted into HIF-2αEC-KO mice (Fig. 7b). SOD3 overexpression improved perfusion of tumors implanted in control but not in HIF-2αEC-KO mice (Fig. 7c, d). Ad-mSOD3-injected tumors in controls but not in HIF-2αEC-KO mice reduced blood vessel number (Fig. 7e) but increased the tumor area covered by vessels as well as their length and diameter (Fig. 7f–h); the branching pattern was unaffected (Fig. 7i). The SOD3-mediated increase in VEC mRNA and protein levels in controls was not observed in HIF-2αEC-KO mouse tumors (Fig. 7j, k; Supplementary Fig. 10c–f). The data indicate that HIF-2α is central to SOD3-induced VEC transcription and enhanced Doxo antitumor activity. Our results suggest that SOD3 improves tumor vascular function by augmenting HIF-2α-dependent VEC expression, probably by increasing NO availability and thus inhibition of PHD activity.

SOD3 correlates with VEC and HIF-2α levels in human cancers. We next measured SOD3 and VEC mRNA levels in freshly frozen samples from a cohort of 102 colorectal carcinoma (CRC) patients (stages I–IV) and in non-tumor samples >10 cm from the primary tumor in the same patients. We found lower SOD3 and VEC mRNA levels in CRC than in non-tumor samples (Fig. 8a, b), with a positive correlation of levels for these genes in CRC samples (Fig. 8c). SOD3 mRNA reduction was not associated to a specific stage or CRC molecular subtype.43

To further study this SOD3/VEC association, we analyzed an independent validation cohort comprised of 87 CRC stage III and 19 non-tumor samples. SOD3 and VEC mRNA levels were again lower in CRC than in non-tumor samples (Fig. 8d, e), with positive correlation between these genes in tumor samples (Fig. 8f). The results thus suggest SOD3 and VEC coregulation in CRC.

Since SOD3 regulates HIF-2α stability in mouse ECs, we tested the association between SOD3 and HIF-2α by immunohistochemistry (IHC) in the epithelial tumor cell compartment and tumor-associated stroma, using a tissue microarray (TMA) of 89 CRC samples (stages I–IV; Fig. 8g); 23.6% of tumor and 8.2% of stromal samples showed no SOD3 or HIF-2α staining. We estimated separate H-scores for each marker in each tumor area; values correlated positively for SOD3 and HIF-2α in stroma (Fig. 8h) and negatively in the tumor compartment (Fig. 8i). SOD3 and HIF-2α might thus be regulated distinctly in epithelial and stromal cells.

As SOD3 regulated HIF-2α stability in mouse EC, we studied the expression of these two genes in the CRC TMA, using CD34 as a label of tumor-associated ECs; 55.4% of CD34+ ECs were SOD3 stained (Fig. 8j; Supplementary Fig. 11). Some sections showed adjacent SOD3-stained and unstained ECs, which implies that this pattern was not artifactual. Most SOD3-stained ECs also showed nuclear HIF-2α accumulation (97.6%). These data suggest that SOD3 stabilizes HIF-2α in human tumor-associated ECs, similar to observations in our mouse tumor models.

**Discussion**

The success of chemotherapy relies on the delivery of sufficient amounts of cytotoxic drugs to kill tumor cells. Progressing tumors have aberrant, hyperpermeable vasculature, which reduces tumor perfusion and restricts diffusion of small molecules from the bloodstream to the tumor interstitial space2,3. Here we identify...
SOD3 upregulation as a target for improving tumor perfusion and selective Doxo delivery through increased VEC transcription via HIF-2α. Elevated SOD3 levels, but not those of a catalytically inactive mutant, reduced monolayer permeability and prevented the VEGF-induced destabilization of AJ. Specific HIF-2α ablation in EC prevented these SOD3 activities, which suggests HIF-2α as a critical SOD3 mediator in vivo.

Reports are contradictory regarding SOD3 influence on tumor progression and angiogenesis. SOD3 not only mediates VEGF-C-induced angiogenesis and metastasis in a specific breast cancer subset but also inhibits angiogenesis by reducing VEGF-A expression or release from the extracellular matrix. A positive feedback loop between Ras activation and SOD3 is suggested to boost cancer cell proliferation. While although SOD3 is downregulated via transcriptional and posttranscriptional mechanisms in a number of human cancers. We found SOD3 mRNA downregulation in two independent CRC cohorts compared to healthy colon tissue, which coincides with low SOD3 protein levels in CRC biopsies. SOD3 silencing thus appears to be common in several malignant tumors.

We used three approaches to upregulate SOD3 in the in vivo tumor environment, one pharmacological (Lov administration) and two genetic (intratumor Ad-mSOD3 injection and EC-specific inducible SOD3 expression). Statins are pleiotropic drugs that can affect the endothelium through various mechanisms. Given that Lov did not improve Doxo delivery or induce VEC expression in tumors implanted in SOD3+/− mice, these Lov effects could be considered SOD3 dependent. Lov upregulated SOD3 significantly in ECs and leukocytes isolated from LLC tumors implanted in WT hosts but not in ECs and leukocytes from tumor-free organs from these mice. These data indicate that Lov upregulates SOD3 in stromal cells via an indirect mechanism that operates in the tumor microenvironment. Our results show that Lov and simvastatin reversed the TNF-α-induced inhibition of SOD3 expression; these statins might thus induce SOD3 by attenuating inflammation. Atorvastatin, added alone or with TNF-α, did not increase SOD3 mRNA. Individual statins can induce specific gene expression profiles, which has been associated with their intracellular concentration. Whether the disparate effects on SOD3 expression between these statins are due to bioavailability or mechanistic differences requires further study.

Another pending question is whether SOD3-induced vascular remodeling depends on its expression in a specific tumor compartment. Lov induced SOD3 in ECs and leukocytes. SOD3 overexpression in ECs was sufficient to increase Doxo effectiveness and reduce tumor vessel permeability, although we observed similar effects after intratumor injection of Ad-mSOD3, which infects and triggers SOD3 expression in tumor and stromal cells. SOD3 is a soluble, secreted enzyme and hence can diffuse in the tumor tissue. Elevation of SOD3 to a level that markedly reduces oxidative radicals in the tumor milieu might thus normalize tumor vasculature as efficiently as perivascular SOD3 expression.

Fig. 5 HIF-2α mediates SOD3-induced VEC transcription. a Relative luciferase activity (RLU) in 1G11 cells cotransfected with SOD3 (or mock) and the full-length VEC promoter or deletion mutants. Values were normalized to the signal in 1G11-mock cells for each promoter (n = 4). b Full-length (−2.5 kb) VEC promoter with binding sites for the main transcription factors. Numbers indicate positions relative to the transcription start site. HRE hypoxia response element, SBS Sox-binding site, EBS Ets-1-binding site. c ChIP analysis of VEC promoter in mock- and SOD3-transfected 1G11 cells using anti-HIF-2α and -KLF-4 antibodies. Coprecipitated DNA fragments were PCR-quantified using primers in a (arrows; n = 5). d RLU in 1G11-mock or -SOD3 cells transfected with VEC promoter HRE mutants. The mutated HRE site is indicated (white square; = 0.3). e Immunoblot analysis of control (shNT) and HIF-2α-silenced (shHIF-2α) 1G11 cells (n = 3). The HIF-2α/tubulin densitometry ratio is shown (bottom). f VEC mRNA levels, using CD31 as reference, in cells as in e. g Relative VEC promoter activity in control and shHIF-2α-1G11 cells transfected with mock or SOD3 plasmids. Data shown as mean ± SEM (b–g). *p < 0.05, **p < 0.001; two-tailed Student’s t-test.
SOD3 stabilizes HIF-2α posttranscriptionally via NO. a Immunoblot analysis of 1G11-mock and -SOD3 cell extracts with anti-HIF-2α and -tubulin antibodies (n = 2). The ratio between bands is shown (bottom). b Immunofluorescence analysis of HIF-2α staining in mock and SOD3-expressing cells (n ≥ 500 cells/condition). c, d Percentage of nuclear area and mean fluorescence intensity in images in b. e Relative VEC promoter activity in IOX2- or Vhcl-treated 1G11-mock and -SOD3 cells. f Scheme of the ELISA used to detect PHD activity. g PHD activity, determined by ELISA, in mock and SOD3-expressing cell extracts. SOD3 levels are shown in these cells as determined by immunoblot (actin loading control; n = 3). h Top, HIF-2α ubiquitination analysis in immunoprecipitates of MG132-treated 1G11-mock and -SOD3 cells at the indicated times. Bottom, rehybridization with anti-HIF-2α antibody. i Immunoblot of HIF-2α in extracts from 1G11-mock and -SOD3 cells cultured in hypoxia (6 h), cycloheximide treated, and cultured in normoxia for the indicated times. Blots were rehybridized for tubulin as loading control. A representative experiment is shown (n = 4). j Quantification of the HIF-2α/tubulin densitometry ratio from i, expressed as the percentage of the ratio at time 0 (hypoxic conditions, 100%). k Representative images of Vhcl- or L-NMMA-treated 1G11-SOD3 cells stained with anti-HIF-2α antibodies. l, m Relative percentage of stained nuclear area and mean fluorescence intensity in Vhcl- or L-NMMA-treated 1G11-mock and -SOD3 cells. Values were normalized to the lowest value in the Vhcl-treated group for each cell type (n ≥ 100 cells/condition). For a, c–e, g, i, l, m, data shown as mean ± SEM from at least three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001; two-tailed Student’s t-test (c, e, g, i, l, m) or two-way ANOVA with Bonferroni post-hoc test (j), showing significant differences between cell lines. Bar, 30 μm.

It is not obvious how an extracellular enzyme might regulate VEC transcription. SOD3 is not itself a transcription factor but can reach the nucleus30, as reported for other SODs31. In the TMA analyses of CRC patients, individual tumor-associated ECs accumulated intracellular/nuclear SOD3. Nuclear SOD3 protects DNA from oxidative damage28 and attenuates NF-κB activity by regulating its oxidative state32. In the case of VEC, we propose that SOD3 inhibits PHD activity to prevent HIF-2α ubiquitination and degradation (Supplementary Fig. 12). Since VEC promoter activation is directly proportional to HIF-2α levels (Supplementary Fig. 9c), SOD3-induced HIF-2α stabilization might promote its binding to the promoter and boost VEC...
Fig. 7  Specific HIF-2α ablation in EC abolishes in vivo SOD3 effects. a, b Growth kinetics of Ad-C- or Ad-mSOD3-injected LLC tumors grafted in control (Cre−; a) or HIF-2αEC-KO mice (b). c, d Images of lectin-FITC-perfused (green), CD31-stained (red) vessels in tumors resected at day 18 (≤1 cm³) from control and HIF-2αEC-KO mice. e–i Vessel density (e), mean area (f), length (g), diameter (h), and branching (i) determined by CD31+ staining in tumors from a, b (n ≥ 25 fields/condition). j VEC mRNA levels, normalized to those of CD31, in tumors in a, b, k VEC-stained area as a percentage of VEC staining in CD31+ structures in images of tumors in a, b (see also Supplementary Fig. 10c–f); n = 10–20 images/group. *p < 0.05; **p < 0.01; ***p < 0.001; two-tailed Student’s t-test. Bar, 50 μm.
transcription. It was not anticipated that SOD3 would trigger specific HIF-2α binding to the −500/−1000-bp region, in which no HIF-2α binding was detected in mock cells. SOD3-induced HIF-2α binding to the VEC promoter might entail not only HIF-2α stabilization but also local modifications to chromatin structure. Moreover, since HIF-2α but not HIF-1α transactivates the VEC promoter, HIF-2α might cooperate with other transcription partners whose activity or location could be SOD3 influenced. We propose that SOD3 effects on HIF-2α and VEC expression depend on increased NO availability due to ·O2− scavenging. This is based on our observation that (i) SOD3 activity and NO synthesis were needed to reduce EC permeability, (ii) NO synthesis blockade reduced and a NO donor increased HIF-2α-mediated VEC promoter activity, and (iii) NO inhibitors prevented SOD3-induced nuclear HIF-2α stabilization.

Fig. 8 Coregulation of SOD3, VEC, and HIF-2α in primary CRC tumors. a, b Scatter plots showing individual data points and mean for SOD3 (a) and VEC (b) mRNA levels in non-tumor (C; n = 13) and CRC samples (CRC; n = 102). c Correlation of SOD3 and VEC mRNA levels in the CRC cohort. d, e Scatter plots as above for SOD3 (d) and VEC (e) mRNA levels in a validation cohort of 19 non-tumor and 87 stage III CRC samples. f Correlation of SOD3 and VEC mRNA levels in the CRC validation cohort. g TMA samples stained for SOD3 and HIF-2α, representative of low (#6) and high (#61) SOD3 levels. h, i Correlation of estimated H-scores for SOD3 and HIF-2α in stromal (h) and tumor (i) compartments. j Representative images from two tumor samples stained for CD34 (red), SOD3 (green), and HIF-2α (blue); the three-color merge is shown; nuclei were counterstained with DAPI (see Supplementary Fig. 11 for single-color images). White lines in the DAPI panel contour CD34-stained areas. c, f, h, i Spearman’s rank correlation test; a, b, d, e *p < 0.05, two-tailed Student’s t-test. Bar, 50 μm (g) and 20 μm (j)
NO has contrasting concentration- and time-dependent effects on EC barrier function. Lack of eNOS reduces VEGF-induced permeability, suggesting a negative NO role in barrier function\textsuperscript{13,14}. Inhibition of endothelial NO production nonetheless accentuates basal and induced alterations in vascular permeability\textsuperscript{15,16}. We also found an inverse, dose-dependent DETA-NONOate effect, which increased VEC transcription and reduced EC permeability at low doses, with opposite effects at high doses. In vivo evidence indicates that perivascular NO accumulation reduces tumor vascular permeability\textsuperscript{17}, a phenomenon similar to that of tumors with high SOD3 levels. The NO reaction with \textbf{O}_2· can modify its effect on barrier stability\textsuperscript{17,18}. The NO donor DETA-NONOate increases its degradation in cerebral ECs; SIN-1 co-addition with SOD3 regulates in human CRC, although further research is needed to establish this relationship between these genes in human CRC. We were unable to confirm this association at the protein level, due to inconsistent results using anti-human VEC antibodies in IHC. SOD3 and HIF-2α noncoregulated in human CRC tissue stroma but were negatively associated in tumor epithelial cells, which suggests that SOD3 stabilizes HIF-2α specifically in stromal but not in neoplastic cells. Most SOD3-stained tumor EC showed HIF-2α staining, whereas unstained ECs lacked HIF-2α. If confirmed, the cell type-specific SOD3 effect on HIF-2α levels might be of therapeutic use, given the antithetical HIF-2α function in tumorigenesis; its upregulation in cancer cells promotes proliferation and neoangiogenesis\textsuperscript{15,16} and, in ECs, induces vascular normalization and enhanced drug delivery\textsuperscript{12,13}.

Some tumors showed adjacent SOD3-stained and unstained EC, which appears not to be an artifact but to indicate true stromal heterogeneity. Although SOD3 and NO are diffusible substances that can spread over short distances, extracellular matrix composition and surrounding non-ECs might confine SOD3/NO dispersion, as for other biomolecules\textsuperscript{36}. A local inflammatory milieu might also preclude SOD3 expression in specific EC.

In summary, our results identify SOD3 as a regulator of VEC transcription in tumor vasculature by NO-dependent stabilization of HIF-2α. This improves perfusion and delivery of chemotherapeutics into murine tumors. SOD3 and VEC are also co-regulated in human CRC, although further research is needed to define SOD3 utility as a predictive biomarker for chemotherapy effectiveness.

**Methods**

**Plasmids and viral constructs.** SOD3 cDNA was obtained from Open Biosystems and the SOD3\textsuperscript{1595C} mutant was generated by directed mutagenesis (QuickChange Site-Directed Mutagenesis Kit, Stratagene), using the primers described\textsuperscript{36}. SOD3 and SOD3\textsuperscript{1595C} were subcloned in the pRIVRES-gfp plasmid and retroviruses produced as described\textsuperscript{36}. SOD3 was also subcloned in the shuttle pCMV vector (AddAxe Xenoviral Vector System, Stratagene), and high titer stocks of Ad-SOD3 and Ad-LacZ were prepared by the Unidad de Producción de Vectores (AdEasy Adenoviral Vector System, Stratagene), and high titer stocks of Ad-SOD3 and Ad-LacZ at the indicated m.o.i. BAEC (Clonetics, Lonza) were cultured on 0.1% gelatin-coated plates with low-glucose DMEM medium with 10% FCS and 2 mM L-glutamine, 20 mM HEPES, 10 ng/ml human epidermal growth factor (EGF; PeproTech), 30 μg/ml bovine pituitary extract (Inovin), 1 μg/ml hydrocortisone (Sigma-Aldrich), and antibiotics. HDMEC were infected with Ad-hSOD3 (Vector Biolabs) and Ad-Lac-Z at the indicated m.o.i. BAEC (Clonetics, Lonza) were cultured on 0.1% gelatin-coated plates with low-glucose DMEM medium with 10% FCS and 2 mM L-glutamine. Other cell lines were cultured under standard conditions. All cell lines were tested regularly for mycoplasma contamination. Primary EC from WT and SOD3\textsuperscript{1595C} mice were isolated from the lung and cultured as described\textsuperscript{36}.

**Human samples.** Freshly frozen stage I–IV tumor samples (cohorts 1) were obtained from the Hospital Clínico San Carlos Tumor Bank between 2001 and 2008,\textsuperscript{37} and we also used formalin-fixed paraffin-embedded tumor samples from stage III CRC patients (cohort 2). For both cohorts, non-tumor samples correspond to resected tissue obtained at >10 cm from the primary tumor in the same patients. These normal colon tissue samples were analyzed histologically by hematoxylin and eosin staining to verify that they did not contain tumor cells; samples in which the pathologist suspected or observed minimal alterations in colon mucosa were discarded. Tumor RNA was isolated using the RNeasy kit (QIAGEN, Germantown, MD), and cDNA was synthesized (SuperScript II RNase H− Reverse Transcriptase, Invitrogen). Human samples were used in strict accordance with the Spanish and American Union laws and regulations concerning care and use of laboratory animals.

**Synergic tumor models.** Adherent growing LLC (>98% live cells) were harvested, and single-cell suspensions of 5 × 10\textsuperscript{4} cells in 100 μl phosphate-buffered saline (PBS) were injected subcutaneously into the right flank of the syngeneic mouse lines indicated above; only female mice were used. Tumors were measured periodically with calipers and tumor volume was calculated using the formula V = \(l \times w \times h / 2\) when tumors reached an average size of 10 mm\textsuperscript{3}, LLC tumor-bearing mice were randomized for treatment by a technician blind to treatments. In tumor experiments involving use of stasis, mice received one daily intraperitoneal dose of VEGF. Tumor cell lines were electroporated into C57BL/6J embryonic stem cells. Chimeras were identified by fluorescence activated cell sorting (FACS) and matured from the ROSA26 locus by homologous recombination, linearized, and electroporated into C57BL/6J embryonic stem cells. Chimeras were identified and crossed with C57BL/6J mice to obtain the germ-line-transmitted heterozygous mixed mice (loxP-SOD3KI). Isox-SOD3 mice were founded by recombination of two different germ-line isox-SOD3KI founders with VE-Cad-Cre\textsuperscript{ERT2} mice\textsuperscript{37}, which has inducible Cre recombinase expression in both modified VEC promoter. Tumorigenesis experiments performed with bi-transgenic mouse lines derived from both Isox-SOD3KI founders yielded similar results. Inducible deletion of HIF-1α in EC (HIF-1α-EC-KO) was achieved by crossing Isox-SOD3KI with VE-Cad-Cre\textsuperscript{ERT2} mice. In all experiments involving SOD3EC\textsuperscript{1595C} and HIF-2α-EC-KO mice, Cre\textsuperscript{+} and Cre\textsuperscript{−} littermates were used for tumorigenesis studies. Mouse experiments were approved by the Comunidad de Madrid (PROEX 399/15) and the CNB Ethics Committees and carried out with 2–5-month-old female mice in strict accordance with the Spanish and American Union laws and regulations concerning care and use of laboratory animals.
(i.p.) injection of Vhcl (5% ethanol) or Lov (15 mg/kg; Sigma-Aldrich) starting at day 7 after LLC inoculation. In tumor experiments involving use of SOD3ΔC-M mice, human formalin-fixed paraffin-embedded tissue was extracted using TRIZOL (Invitrogen, Carlsbad, CA) and from isolated cells from tumors and healthy organs, and cell lines, using Tri-Reagent (Sigma-Aldrich). For in vitro experiments, Lov was activated as described40. Tumor-bearing mice were isolated by positive selection of CD4+ cells with sheep anti-rat magnetic beads (Invitrogen) precoated with the anti-CD45 antibody. Lungs and spleen showed no macroscopic or microscopic signs of metastasis.

**Immunohistochemistry.** All methods for IHC and IF of mouse tumors have been described33,34. Brieﬂy, tumors were excised at days 16–18 after tumor cell inoculation and snap-frozen in Tissue Freezing Medium (OCT; Jung) or ﬁxed with 10% neutral buffered formalin (3 h) and parafﬁn embedded. Sections (5–20 μm) were prepared and used directly (frozen tissue) or deparafﬁnized, rehydrated, and subjected to heat-induced epitope retrieval in citrate buffer (0.01 M sodium citrate pH 6, 20 min). For immunostaining, the following rabbit antibodies were used: anti-CD31 (MEC13.3, BD Bioscience), -SOD3 (Cloud Clone), -VEC (LS-B2138, LSBio), -HIF-2α (PAI-32216; Thermo Fisher Scientiﬁc), and -3NT (#066–284, Cell Signaling). Sections were incubated with appropriate ﬂuorescently conjugated secondary antibodies (Alexa 488 or 568, Molecular Probes) or with peroxidase-labeled antibody (goat anti-rabbit or -mouse, Vector Laboratories) and hematoxylin counterstaining. Sections were mounted with 4,6-diamidino-2-phenylindole (DAPI)–containing Fluoromount-G (SouthernBiotech; ﬂuorescence analyses) or Dako Faramount Aqueous Mounting Medium (Dako; conventional IHC) and analyzed with an Olympus Fluoview 1000 confocal microscope with a 12-bit plan Apo objective or with a Leica (DM RB) microscope equipped with an Olympus DP70 camera.

**TMA analyses.** Microarrays were prepared from iCRc samples and IHC was performed in deparafﬁnized samples after antigen retrieval in citrate buffer (pH 6.0, 20 min) by incubation with goat anti-SOD3 (AF3420, R&D Systems), rabbit anti-HIF-2α (NB100-122, Novus Biologicals), or mouse anti-CD34 antibodies (QBEnd-10, M765 Dako), followed by appropriate peroxidase-labeled secondary antibodies. The reaction was developed with AEC or diaminobenzidine (CD34) as chromogens, and hematoxylin counterstained. In all cases, sections from normal colon mucosa distant from the tumor site were used as controls. Staining was evaluated in a Leica DM500 optical microscope by a single pathologist (M.F.-A.) blinded to experimental data. The percentage of stained cells and staining intensity (scored as 1–3) were recorded for each gene, and the H-score was calculated as the product of these parameters for the epithelial tumor cell compartment and for tumor-associated stromal cells. In IF analyses, samples were incubated with all three antibodies, followed by appropriate secondary antibodies. Images were captured on an Olympus Fluoview 1000 confocal microscope.

**HIF-1α/2α staining and nuclear quantiﬁcation.** Immunofluorescence analyses of cultured EC were performed in 1% gelatin-coated Nunc Lab-Tek chamber slides. Untreated or L-NMMA (100 μM; Cayman)-treated cells were ﬁxed with 4% paraformaldehyde (PFA; 10 min, 20 °C) for HIF-1α staining or with ethanolic acid (95.5, 1 min, −20 °C) for HIF-2α staining. Cells were then permeabilized with 0.1–0.3% Triton X-100 (5 min, 20 °C) and stained with rabbit anti-HIF-1α (PA1-16061) or -HIF-2α (PAI-32216; Thermo for 1G11 cells; NB100-122; Novus Biologicals, antihuman) for 1G11 cells treated with CoCl2 (100 μM, 3 h, 37 °C) before fixing. Images were acquired with a Leica DMI6000B microscope equipped with a Hamamatsu camera ORCA-R2 (HIF-2α). An open source MATLab-based computational platform was developed for automatic quantiﬁcation of HIF-2α-associated ﬂuorescence after background subtraction. Nuclei were segmented using IMAGI images and the segmentation applied to the Alexa546 ﬂuorescence to calculate the ratio of HIF-2α-stained pixels within the nuclear area; the ratio of nuclei staining to total nuclei staining. Region of interest analysis was performed on the 1G11 cell line, and the H-score determined 30 μm thick sections were analyzed with a Radiance 2100 confocal system (BioRad) on a Axiovent 200 microscope (Zeiss; excitation/detection 488/500–560 nm). In some experiments, vessels were 3D-reconstructed from section stacks (1 μm step size) with Imaris v7.3.1 software (Bitplane). The number of nuclei staining or the area stained (fixed 1G11 cells) was then calculated in tumor sections using ImageJ software. RGB images were transformed to 16-bit and, after threshold adjustment, the Analyze Particle tool was applied using settings.
for particle size (>10 microns) and circularity (0–1). Perfusion was calculated as the percentage of double-positive (CD31+ lectin) to CD31+ structures.

CD31 staining and quantification of blood vessel parameters. End-point vessels were snap-frozen in OCT and 20 μm sections were stained sequentially with anti-CD31 and fluorocein-labeled secondary antibodies. The number of CD31-stained structures and average size were determined with Image J as above. To determine other vessel parameters, we used histogram equalization to increase contrast and allometry detection of small and lightly stained structures. A Hessian-based Frangi filter was then applied to enhance vessel fibrillar structure.41 A vessel mask was obtained by applying Otsu thresholding; this mask was used to visualize vessel skeleton using morphological thinning operations to calculate length and branch points of each vessel. Euclidean distance transform from the vessel mask to the edge of segmentation was also performed. Vessel diameter was calculated by the values of the Euclidean distance transform lying on the skeleton (central values). All calculations were performed using MATLAB Release 2017a (The MathWorks). For Vhcl- and Lov-treated tumors, lectin-perfused images (see above) were used for analyses.

SEM was performed as reported.33

VECA staining and quantification. Tumor-bearing mice (day 17–20 post-LIHC inoculation) were perfused with 2% PFA in PBS, fixed in PFA, and included in OCT. Tumor sections were stained with anti-VECA and -CD31 antibodies, followed by appropriate labeled secondary antibodies, and analyzed in an Olympus Fluoview 1000 confocal microscope with a x60 1.4 oil plan-Apo objective. Images were obtained with 8-bit with Imaris, and, after threshold adjustment, the Image calculator tool was used to select CD31- and VECA-stained coincident regions. The ratio between VECA- and CD31-stained areas was calculated and expressed as a percentage.

For quantification of VECA-stained length in tumor vessels, images were segmented, using imageJ and, after threshold adjustment, the Image calculator tool was used to select blood vessels. Hysteresis thresholding was applied to VECA staining in the CD31 area. Morphological thinning was run to measure the length of VECA-stained structures using MATLAB.

For VECA staining in human and mouse EC, cells were plated on 1% gelatin-coated Lab-Tek chamber slides (Nunc), fixed with 4% PFA (10 min, 20 °C), permeabilized with 0.25–0.3% Triton X-100 (5 min, 20 °C) and stained with appropriate antibodies for mouse or human VECA (see above). In some experiments, IG11-mock and -SOD3 cells were pretreated with VEGF165 (50 ng/ml, 2 h; Pentrexotic 450–520) before staining. Images were acquired with the Olympus Fluoview 1000 system. Functional length and gap index were quantified as described, with a minimum of 5 fields/condition.

Permeability assays. In vivo vessel leakage was analyzed in tumor-bearing mice (day 17) by i.v. co-injection of Texas Red-conjugated dextran 70 kDa (250 μg) Molecular Probes) and FITC-lectin (100 μg). After perfusion with 2% PFA in PBS, tumors were fixed (2% PFA, 3 h) and snap-frozen in Optimal Cutting Temperature (OCT) compound and stained by confocal microscopy (Olympus Fluoview1000), and images were quantified using the confocal software (FV10-ASW, Olympus). Vessel leakage is the ratio between fluorescence intensity of extravasated dextran and perfused vessel counts.

For in vitro permeability analyses, 2 x 10^5 IG11 or HDMEC (stable, transfected with Ad-mSOD3, or infected with Ad-αSOD or control) were seeded on 24-well plates and, after 24 h culture. Cell monolayers were transduced with Ad-C and Ad-mSOD3 viruses and were incubated the next day with the indicated plasmids, or infected with Ad-hSOD3 or control. Cells were incubated with p9xHIF-Luc plus pRVIRES-gfp (mock control), pVRVSOD3-IRES-gfp, pDNA3-hSOD3, pRVSOD3-IRES-gfp, pHE4SPORTS-HIF1α, and pSV-SOD3-EVLuc in parallel and quantified by RT-qPCR. Luciferase activity, with that of control set as 1.0.

Hydroxyase activity assay. Endogenous PHD activity was measured in mock- and SOD3-transfected cells using HIF-1α as substrate. Briefly, cells were transiently transfected with pVRVSOD3-IRES-gfp or pRVIRES-gfp using the calcium phosphate method; transfection efficiency was 70–90%, as analyzed by FACS using GFP as marker. Cell extracts were prepared at 48 h post-transfection using a hypotonic buffer (20 mM Tris-HCl pH 7.5, 5 mM KCl, 1.5 mM MgCl2) (2 h). After mechanistic disruption with a Dounce homogenizer, and passage through a 30-g needle. Soluble material was obtained by centrifugation (12,000 × g, 30 min, 4 °C). The PHD activity of these extracts was analyzed by ELISA.

Promoter assays. pGL3-VECA-Luc (2.4 kb VEC promoter)56 and p9xHIF-Luc57 plasmids were provided by O. Xu (King’s College London British Heart Foundation Centre) and L. del Peso (Universidad Autónoma de Madrid), respectively. Serial 5′-deletion mutants of the VEC promoter were generated by PCR using pGL3-VEC-Luc as template. HRE sites in the VEC promoter were mutated by replacing the CAATTG consensus in the HRE consensus with AAAGAAGG (5′-CAATTG to 5′-AAAGAAGG) with a TAATTTG using Mutazyme II (New England Biolabs). Following oligonucleotides were site-directed mutagenesis (HRE1: 5′-GCTGAAAGTGTT GTCTGTCATTCTTCTACGGTCGCCG3′; HRE2: 5′-CCTCGGTGTTGCCTAGG TCAAAGAAGGCTTTACCAACG3′, and HRE3: 5′-GATTAGAGAAAGGCGCT CAGATTGTCCTGATTG3′).

For the reporter assays, IG11 or JTM3 fibroblast cells were transiently transfected using Lipofectamine 3000 (Thermo Fisher Scientific) with a mixture of plasmids (500 ng total DNA) containing pGL3-VEC-Luc, pGL3-VEC-Luc mutants or p9xHIF-Luc plus pRVIRES-gfp (mock control), pVRVSOD3-IRES-gfp, pDNA3-hSOD3, pRVSOD3-IRES-gfp, pHE4SPORTS-HIF1α, and pSV-SOD3-EVLuc in parallel, at a 6:3:1 ratio (for IG11) or 4:8:1 (for JTM3). In experiments involving different HIF-1α and HIF-2α doses, the transfected DNA amount was kept constant with an empty pDNA3 plasmid. In some experiments, transfected cells were incubated with DETA-NONOate, L-NAME, or IOX2 (Cayman), using an equivalent DMSO concentration as vehicle. Firefly and Renilla luciferase activities were measured 72 h post-transfection using the Dual-Luciferase Reporter Assay System (Promega). Relative promoter activity was defined as the ratio of firefly luciferase activity, with that of control set as 1.0.
Statistical analysis. For in vitro experiments, data are shown as mean ± SEM of at least three independent experiments with at least three technical replicates. For in vivo experiments, data are shown as mean ± SEM of individual mice pooled from at least two independent experiments. Sample size in animal studies was estimated using the power method, and values corrected for 20% attrition. For staining of in vivo material, at least five mice were used. For data with normal distribution and homogeneity of variances, statistical significance was calculated with a two-tailed Student’s t-test for comparison of two independent groups and one-way or two-way ANOVA with Dunnett’s, Tukey’s, or Bonferroni’s post-hoc test for multiple comparisons. When the above requirements were not fulfilled, data were analyzed using non-parametric tests. Correlation analyses were performed using the non-parametric Spearman’s rank correlation coefficient. Differences were considered significant when p < 0.05. All statistical analyses were performed using the Prism software.

Data availability. The authors confirm that all relevant data and materials supporting the findings of this study are available on reasonable request. This excludes materials obtained from other researchers, who must provide their consent for transfer.

Code availability. MATLAB programs generated for HIF-2α image quantification can be accessed on reasonable request.

Received: 31 January 2017 Accepted: 18 January 2018
Published online: 08 February 2018

References
1. Giannotta, M., Trani, M. & Dejana, E. VE-cadherin and endothelial adherens junctions: active guardians of vascular integrity. Dev. Cell 26, 441–454 (2013).
2. Carmeliet, P. & Jain, R. K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 10, 417–427 (2011).
3. Azzi, S., Hebda, J. K. & Gavard, J. Vascular permeability and drug delivery in cancers. Front. Oncol. 3, 211 (2013).
4. Gavard, J. Endothelial permeability and VE-cadherin: a wacky comradeship. Cell Adh. Migr. 8, 1 (2014).
5. Taddie, A. et al. Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat. Cell Biol. 10, 923–934 (2008).
6. Crosby, C. V. et al. VE-cadherin is not required for the formation of nascent blood vessels but acts to prevent their disassembly. Blood 105, 2771–2776 (2005).
7. Muz, B., de la Puente, P., Azah, F. & Azah, A. K. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl.) 3, 83–92 (2015).
8. Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271–275 (1999).
9. Ivan, M. et al. HIFAlpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464–468 (2001).
10. Semenza, G. L. Hypoxia-inducible factors in physiology and medicine. Cell 148, 399–408 (2012).
11. Takeda, K., Cowan, A. & Fong, G. H. Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation 116, 774–781 (2007).
12. Mazzone, M. et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136, 839–851 (2009).
13. Leite de Oliveira, R. et al. Gene-targeting of Phd2 improves tumor response to chemotherapy and prevents side-toxicity. Cancer Cell 22, 263–277 (2012).
14. Le Bras, A. et al. HIF-2 alpha specifically activates the VE-cadherin promoter independently of hypoxia and in synergy with Ets-1 through two essential ETS-binding sites. Oncogene 26, 7480–7489 (2007).
15. Chen, W. et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 439, 112–117 (2006).
16. Cho, H. et al. On-target efficacy of a HIF-2 alpha antagonist in preclinical kidney cancer models. Nature 539, 107–111 (2016).
17. Metzen, E., Zhou, J., Jellmann, W., Fandrey, J. & Brune, B. Nitric oxide impairs normoxic degradation of HIF-1 alpha by inhibition of prolyl hydroxylases. Mol. Biol. Cell 14, 3470–3481 (2003).
18. Kashwagi, S. et al. Perivascular nitric oxide gradients normalize tumor vasculature. Nat. Med. 14, 255–257 (2008).
19. Predescu, D., Predescu, S., Shimizu, J., Miyawaki-Shimizu, K. & Malik, A. B. Constitutive eNOS-derived nitric oxide is a determinant of endothelial junctional integrity. Am. J. Physiol. Lung Cell. Mol. Physiol. 289, L371–L381 (2005).
20. Mazei, N. et al. S-Nitrosoylation of arginine residues in phosphodiesterases inhibits the growth of B16 melanomas in mice. Mol. Cancer Res. 1, 871–881 (2003).
46. Teoh, M. L., Fitzgerald, M. P., Oberley, L. W. & Domann, F. E. Overexpression of extracellular superoxide dismutase attenuates heparanase expression and inhibits breast carcinoma cell growth and invasion. Cancer Res. 69, 6355–6363 (2009).
47. Laukkaniemi, M. O., Cammarota, F., Esposito, T., Salvatore, M. & Castellone, M. D. Extracellular superoxide dismutase regulates the expression of small gtpase regulatory proteins GEFs, GAPS, and GDP. PLoS ONE 10, e0121441 (2015).
48. Zhang, X. et al. MicroRNA-21 modulates the levels of reactive oxygen species by targeting SOD3 and TNFα. Alpha. Cancer Res. 72, 4707–4713 (2012).
49. Gbelcova, H. et al. Variability in statin-induced changes in gene expression profiles of pancreatic cancer. Sci. Rep. 7, 44219 (2017).
50. Okawara, T. et al. Nuclear translocation of extracellular superoxide dismutase. Biochem. Biophys. Res. Commun. 296, 54–61 (2002).
51. Tsang, C. K., Liu, Y., Thomas, J., Zhang, Y. & Zheng, X. F. Superoxide dismutase 1 acts as a nuclear transcription factor to regulate oxidative stress resistance. Nat. Commun. 5, 3446 (2014).
52. Laurila, J. P., Laatikainen, L. E., Castellone, M. D. & Laukkanen, M. O. SOD3 reduces inflammatory cell migration by regulating adhesion molecule and cytokine expression. PLoS ONE 4, e5786 (2009).
53. Di Lorenzo, A. et al. eNOS-derived nitric oxide regulates endothelial barrier function through VE-cadherin and Rho GTPases. J. Cell Sci. 126, 5541–5552 (2013).
54. Kraehling, J. R. & Sessa, W. C. Enhanced eNOS activation as the fountain of youth for vascular disease: Is BPIFB4 what Ponce de Leon was looking for? Circ. Res. 117, 309–310 (2015).
55. Baldwin, A. L., Thurston, G. & al Naemi, H. Inhibition of nitric oxide synthesis increases venular permeability and alters endothelial actin cytoskeleton. Am. J. Physiol. 274, H1776–H1784 (1998).
56. Kihara, T., Ito, J. & Miyake, J. Measurement of biomolecular diffusion in extracellular matrix condensed by fibroblasts using fluorescence correlation spectroscopy. PLoS ONE 8, e82382 (2013).
57. Mira, E. et al. A role for chemokine receptor transactivation in growth factor signaling. EMBO Rep. 2, 151–156 (2001).
58. Ogando, J. et al. Notch-regulated miR-223 targets the aryl hydrocarbon receptor pathway and increases cytokine production in macrophages from rheumatoid arthritis patients. Sci. Rep. 6, 20223 (2016).
59. Rackov, G. et al. p21 mediates macrophage reprogramming through regulation of p50–NF-κB and IFN-beta. J. Clin. Invest. 126, 3089–3103 (2016).
60. Tardaguila, M. et al. CX3CL1 promotes breast cancer via transactivation of the EGF pathway. Cancer Res. 73, 4461–4473 (2013).
61. Jakobisiak, M., Bruno, S., Skierski, J. S. & Darzynkiewicz, Z. Cell cycle-specific effects of lovastatin. Proc. Natl. Acad. Sci. USA 88, 3628–3632 (1991).
62. González-Martín, A., Gómez, L., Lustgarten, J., Mira, E. & Mañes, S. Maximal T cell-mediated antitumor responses rely upon CCR3 expression in both CD4 (+) and CD8 (+) T cells. Cancer Res. 71, 5455–5466 (2011).
63. McCarty, K. S. Jr., Miller, L. S., Cox, E. B., Konrath, J. & McCarty, K. S. Jr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch. Pathol. Lab. Med. 109, 716–721 (1985).
64. M. S., B. V., M. P.-C., T.O., and S.M.-P. provided samples and reagents. C.G.N. and G.F. determined Doxo. P.M.G. developed MATLAB programs and quantified HIF-2α images. M.I.F.-A. quantified T.M.A. E.M., L.C.-R., M.I.-F., A.M.-R., M.T., I.H.-M., and R.A.L. performed most of the experiments. S.M. wrote the manuscript. All authors read and discussed the manuscript. Additional information

Acknowledgements

The authors thank A González-Martín for critical reading; L Iruela-Arispe, A Mantovani, Q Xu, L del Peso, and LM Redondo for reagents; MC Moreno and S Escudero for help with cell sorting; RM Peresil, N Rodriguez, N Dalmau, and JM Ballestero for technical assistance; and C Mark for editorial support. This work was supported by grants from the Spanish MINECO (SAF2014-54475-R, SAF2017-83732-R; AEI/FEDER, EU), the Comunidad de Madrid (B2017/BMD-3733), Immunothercan-GM, and the Domingo-Martínez Foundation to S.M.-P. is supported by a Miguel Servet contract (CP09/ 00100), L.C.-R. is funded by the FPU program, and I.H.-M. and D.M.-R. were AECC summer fellowship recipients.

Author contributions

E.M. and S.M. conceived the study. E.D.-R., B.P.-V., M.P.-C., T.O., and S.M.-P. provided animal care. M.J.F.-A. performed experiments. E.M. and S.M. critically read and approved the manuscript. All authors read and discussed the manuscript.

Additional information

Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-018-03079-1.

Competing interests: The authors declare no competing financial interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.